Claudino Felipe Cesar de Almeida, Gonçalves Leonardo, Schuch Felipe Barreto, Martins Hugo Roberto Sampaio, da Rocha Neusa Sica
Center of Clinical Research and Center of Experiamental Research, Hospital de Clínicas de Porto Alegre (HCPA), Post-Graduation Program in Psychiatry and Behavioral Sciences, Federal University of Rio Grande do SUl (UFRGS), Porto Alegre, Brazil.
Department of Sports Methods and Techniques, Federal University of Santa Maria (UFSM), Santa Maria, Brazil.
Front Psychiatry. 2020 May 19;11:445. doi: 10.3389/fpsyt.2020.00445. eCollection 2020.
Brain-derived Neurotrophic Factor (BDNF) is considered the main cerebral neurotrophin and is produced in the central neural system and peripherals. Its levels are reduced in patients with several psychiatric disorders, but it is unclear if the response to psychotherapy can alter its concentration.
To carry out a systematic review evaluating the effects of individual psychotherapy in BDNF levels in patients with mental disorders.
The databases PubMed, EMBASE, PsycArticles, SciELO, Web of Science, and CENTRAL; the last search was performed on October 2019 for trials evaluating the effects of individual psychotherapy in BDNF levels in adults with mental disorders. PROSPERO registration: CRD42018108144.
Eight of 293 studies were included. A rise in BDNF levels was observed in depressive patients when psychotherapy was combined with medication. Patients with post-traumatic stress disorder (PTSD) who responded to therapy presented a raise in BDNF levels mostly when combined with physical activity. There was a rise in BDNF levels in those who responded to psychotherapy in patients with bulimia, in borderline patients, and in insomniacs.
The BDNF seems to present variations after psychotherapy especially in patients with bulimia, PTSD, insomnia, and borderline. These subjects also have symptom reduction. Thereby, BDNF could be a supplemental tool to analyze the success to psychotherapy. BDNF levels in patients with major depression after therapy are still controversial and the short follow-up of most studies is a limiting factor.
脑源性神经营养因子（BDNF）被认为是主要的脑神经营养因子，在中枢神经系统和外周均有产生。在患有多种精神疾病的患者中其水平会降低，但尚不清楚心理治疗的反应是否会改变其浓度。
进行一项系统评价，评估个体心理治疗对精神障碍患者BDNF水平的影响。
检索数据库PubMed、EMBASE、PsycArticles、SciELO、Web of Science和CENTRAL；最近一次检索于2019年10月进行，以查找评估个体心理治疗对成年精神障碍患者BDNF水平影响的试验。PROSPERO注册号：CRD42018108144。
293项研究中有8项被纳入。抑郁患者在心理治疗与药物联合使用时观察到BDNF水平升高。对治疗有反应的创伤后应激障碍（PTSD）患者，大多在与体育活动联合时BDNF水平升高。贪食症患者、边缘性人格障碍患者和失眠症患者中，对心理治疗有反应者的BDNF水平升高。
BDNF似乎在心理治疗后会出现变化，尤其是在贪食症、PTSD、失眠症和边缘性人格障碍患者中。这些患者的症状也有所减轻。因此，BDNF可能是分析心理治疗成功与否的一种辅助工具。重度抑郁症患者治疗后的BDNF水平仍存在争议，且大多数研究随访时间短是一个限制因素。
